Login
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc.

monterosatx.com

What Do They Do?

Develops small-molecule drugs that direct the body to break down disease-related proteins, for patients with immune-mediated diseases, inflammatory conditions and cancer.

How Do They Make Money?

Pharmaceutical partners pay upfront to license programs and support research; further payments may follow when development milestones are met, with royalties on licensed-product sales. The company also earns collaboration revenue as it conducts research over time and when a license is transferred.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical companies collaborate directly with Monte Rosa: Roche selects oncology and neuroscience targets for discovery work, while Novartis licenses programs in immunology and inflammation.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +326%
vs $12.8M in Q3 FY2025
Net income
▲ Turned profitable
vs −$27.1M in Q3 FY2025

Licensing programs The company has moved from retaining worldwide rights to its pipeline to licensing selected programs to pharmaceutical partners, which take on later development and commercialization.

Cancer focus The newer description centers the lead cancer program on metastatic castration-resistant prostate cancer; the earlier report covered several MYC-driven tumor types, including lung and neuroendocrine cancers.

Who Do They Compete With?

Competes with C4 Therapeutics, Nurix Therapeutics, Kymera Therapeutics, Bristol-Myers Squibb, Novartis, AstraZeneca, Roche, Novo Nordisk, Ventyx Biosciences, BioAge Labs, NodThera, Pfizer, Merck, BeOne Medicines, and Incyte

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support